| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KRT19 |
| Uniprot No | P08727 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-400aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMTSYSYR QSSATSSFGG LGGGSVRFGP GVAFRAPSIH GGSGGRGVSV SSARFVSSSS SGAYGGGYGG VLTASDGLLA GNEKLTMQNL NDRLASYLDK VRALEAANGE LEVKIRDWYQ KQGPGPSRDY SHYYTTIQDL RDKILGATIE NSRIVLQIDN ARLAADDFRT KFETEQALRM SVEADINGLR RVLDELTLAR TDLEMQIEGL KEELAYLKKN HEEEISTLRG QVGGQVSVEV DSAPGTDLAK ILSDMRSQYE VMAEQNRKDA EAWFTSRTEE LNREVAGHTE QLQMSRSEVT DLRRTLQGLE IELQSQLSMK AALEDTLAET EARFGAQLAH IQALISGIEA QLGDVRADSE RQNQEYQRLM DIKSRLEQEI ATYRSLLEGQ EDHYNNLSAS KVL |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KRT19重组蛋白的模拟参考文献示例(非真实文献，仅供格式参考)：
---
1. **标题**：Expression and Purification of Recombinant Human KRT19 in *E. coli* for Antibody Production
**作者**：Zhang Y, et al.
**摘要**：本研究报道了在大肠杆菌系统中高效表达重组人KRT19蛋白的方法，通过His标签纯化获得高纯度蛋白，并用于免疫小鼠制备特异性单克隆抗体，为癌症诊断试剂开发提供材料基础。
2. **标题**：Recombinant KRT19 as a Biomarker in Non-Small Cell Lung Cancer Detection
**作者**：Lee S, Kim J.
**摘要**：利用重组KRT19蛋白建立高灵敏度ELISA检测方法，验证其在非小细胞肺癌患者血清中的诊断价值，显示其与组织病理学结果高度一致，提示其在液体活检中的潜在应用。
3. **标题**：Structural Characterization of Recombinant KRT19 and Its Role in Epithelial Cell Adhesion
**作者**：Smith R, et al.
**摘要**：通过圆二色谱和质谱分析重组KRT19的二级结构，并发现其过表达可增强上皮细胞间粘附，揭示KRT19在维持上皮完整性中的分子机制。
4. **标题**：Recombinant KRT19 Fusion Protein Enhances Drug Delivery in Breast Cancer Models
**作者**：Wang H, et al.
**摘要**：构建KRT19-荧光蛋白融合载体，证明其在乳腺癌细胞中靶向递送化疗药物的能力，为基于角蛋白的靶向治疗策略提供实验依据。
---
如需真实文献，建议通过PubMed或Web of Science以关键词“recombinant KRT19”或“keratin 19 recombinant”检索近期研究。
Keratin 19 (KRT19), a member of the type I intermediate filament protein family, is a structural component of the cytoskeleton in epithelial cells. It plays a critical role in maintaining cellular mechanical integrity, regulating cell signaling, and supporting tissue organization. KRT19 is widely expressed in simple and stratified epithelia, including the gastrointestinal tract, mammary glands, and pancreas. Unlike many keratins, it lacks a terminal tail domain, contributing to its distinct biochemical properties.
Recombinant KRT19 protein is engineered using biotechnological methods, often expressed in prokaryotic (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian or insect cells) to ensure proper folding and post-translational modifications. The purified protein typically retains epitopes for antibody recognition, making it valuable in research and diagnostics. Its production enables studies on epithelial cell biology, cancer progression, and regenerative medicine.
KRT19 has gained clinical relevance as a biomarker. It is overexpressed in carcinomas, such as breast, lung, and pancreatic cancers, and is a key component of liquid biopsy assays (e.g., circulating tumor cell detection). For instance, KRT19 forms the basis of the CA15-3 and CYFRA 21-1 tests, used to monitor breast and lung cancer progression, respectively. Recombinant KRT19 serves as a standard in these diagnostic platforms.
In research, recombinant KRT19 aids in investigating epithelial-mesenchymal transition (EMT), metastasis, and stem cell properties. It is also utilized to develop antibodies, study keratinopathies, and explore therapeutic targets. Recent studies highlight its role in drug resistance and interactions with signaling pathways like Wnt/β-catenin.
Despite its utility, challenges remain in mimicking native post-translational modifications in recombinant forms, which may affect functional studies. Ongoing efforts focus on optimizing expression systems to enhance physiological relevance. Overall, recombinant KRT19 is a pivotal tool bridging basic research and clinical applications in epithelial biology and oncology.
×
